Read More Pharma Industry News IntraBio files first-ever FDA application for an Ataxia-Telangiectasia drug with AQNEURSA sNDA submission IntraBio filed the first-ever FDA application for Ataxia-Telangiectasia via an AQNEURSA sNDA. Read what the Phase III data means for patients and the rare disease market. bySrinathMarch 20, 2026